Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Thursday the availability of Trientine Hydrochloride Capsules USP in 250 mg.
The US Food and Drug Administration (FDA) approved Trientine Hydrochloride Capsules USP in 250 mg are a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules. The product can be stored at room temperature (20°C to 25°C or 68°F to 77°F) throughout the product shelf life of 24 months.
Dr. Reddy's Trientine Hydrochloride Capsules USP in 250 mg are available in 100 count bottles.
For the most recent 12 months ended December 2019, the Syprine brand and generic products had US sales of approximately USD94.2m MAT, according to IMS Health. Syprine is a trademark of Alton Pharma.
Dr. Reddy's Laboratories to Acquire Select Business Divisions of Wockhardt in India
Dr. Reddy's Laboratories to purchase select business divisions of Wockhardt in India for INR18.5bn
Sun Pharma Introduces Absorica LD Capsules in USA for Management of Severe Recalcitrant Nodular Acne
Dr. Reddy's Laboratories releases Trientine Hydrochloride Capsules USP in 250 mg for US market
Towa Pharmaceutical completes acquisition of Esteve's generics division
Geneyork and Lannett Company start commercial shipment of Deltasone tablets
FDA Approves Ajovy Injection Autoinjector
Par Pharmaceutical commences shipping authorised generic version of Allergan's Carafate